Posts

VenaSeal ‘Vein Glue’ Approved By FDA To Treat Varicose Veins

VenaSeal ‘Vein Glue’ Approved By FDA To Treat Varicose Veins

Earlier this week, The U.S. food and Drug Administration (FDA) approved the VenaSeal closure system to permanently treat varicose veins by sealing the affected superficial veins using an adhesive agent.

This treatment has been usedvenaseal in Europe, and will soon be available to vein specialists and their patients in the United States.

According to the manufacturer’s website:

‘The VenaSeal Sapheon Closure System is a unique, minimally invasive treatment that uses a safe-for-the-body medical glue to quickly and effectively treat varicose veins (venous reflux disease). Using ultrasound, a doctor will guide a tiny catheter through a small access site in the skin and into the diseased area of the vein. Next, the VenaSeal dispenser delivers a very small amount of medical glue to close the vein. Once the affected vein is closed, blood is immediately re-routed through other healthy veins in the leg.

Unlike other treatments, VenaSeal does not require anaesthesia to be injected into the leg via multiple needle sticks (tumescent anesthesia), and because there are no pre-procedures drugs involved, patients can return to their normal activities right after the treatment. Unlike heat-based procedures, with VenaSeal there is no risk of skin burns or nerve damage. VenaSeal usually does not require any post-treatment pain medication or uncomfortable compression stockings.’

 

 

New Foam Treatment of Varicose Veins

In November of 2013, the US Food and Drug Administration (FDA)  approved Varithena,™   a new type of foam treatment for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. Varithena is a pharmaceutical-grade, low-nitrogen, polidocanol foam dispensed from a canister device. In two pivotal, placebo-controlled Phase III trials, VANISH-1 and VANISH-2, Varithena achieved a clinically meaningful improvement in the symptoms of superficial venous incompetence and the appearance of visible varicosities and addressed the underlying venous incompetence in the majority of patients treated. Varithena (polidocanol injectable foam) is a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein system above and below the knee.  Varithena improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.  Treatment is a minimally invasive, non-surgical procedure that requires neither tumescent anesthesia nor sedation.  Foam sclerotherapy has been used for years by medical doctors. What is new with Varithena , is that the foam is pre-made with low-nitrogen as opposed to room air, and is dispensed in a proprietary canister.   It is not yet available in doctors offices. Making Foam

Radiofrequency Technology: The Next Wave for Treating Varicose Veins

The next generation technology for treating varicose veins is here. La Jolla Vein Care is pleased to announce its newest device for treating unsightly, bulging veins of the legs- the Venefit™ procedure. The procedure utilizes radiofrequency energy to cause the veins to collapse and eventually vanish. The procedure allows for a quick, comfortable recovery and immediate return to normal activities. The next wave of technology for vein treatment is here-and it’s at La Jolla Vein Care.